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. In addition, the formal diagnosis of 'atypical anorexia nervosa' was created within the Other Specified Feeding or Eating Disorder (OSFED) category of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (known as DSM-5) for those who are not low weight but meet anorexia nervosa psychological criteria 1 . Amenorrhea was removed as a criterion due to the recognition that endocrine dysregulation in anorexia nervosa is variable, and that some women with low weight and all the psychiatric features of anorexia nervosa continue to have regular menses 2 . Before these revisions, the incidence of anorexia nervosa in Europe had been stable since the 1970s according to primarycare-based records 3, 4 . However, the incidence seemed to be increasing among adolescent and young women aged 10-24 years according to a primary-care-based study in the Netherlands and a population-based study in Rochester, Minnesota, USA 4, 5 . Since, and perhaps due to, the advent of DSM-5 and broadening of the diagnostic criteria for anorexia nervosa, investigators have seen a substantial increase in the prevalence of anorexia nervosa 6, 7 . Although the disease most commonly affects young women, a population-based study in Europe reported a 0.17% lifetime prevalence of anorexia nervosa in women >45 years of age 8 . Anorexia nervosa also affects adolescent boys and men, although disease prevalence was 8.1 times higher in women than in men in a population-based study in the USA 9 . In women, anorexia nervosa is characterized by global endocrine dysregulation, including hypothalamic-pituitary axis dysfunction and alterations in adipokine and appetite-regulating hormone levels 10 . Although these endocrine disturbances are mostly an adaptation to the low energy state, they can exert deleterious effects on skeletal health and neuropsychiatric comorbidities. Understanding the mechanisms responsible for endocrine complications of anorexia nervosa is important given the severity and chronic nature of the disease. Approximately 50% of women with anorexia nervosa recover after therapy 11 , ~30% only partially recover, and the remainder experience recurrent patterns of remission and relapse or chronic disease 12, 13 . In this Review, we discuss the endocrine complications of anorexia nervosa, including dysregulation of hypothalamic-pituitary axis hormones, adipokines and appetite-regulating hormones. We elaborate on the evidence that most of these endocrine disturbances are adaptive to the low energy state of chronic starvation; consequently, appropriate treatment consists of addressing the underlying eating disorder. We also discuss how this endocrine dysregulation contributes to common comorbidities in anorexia nervosa, that is, impaired skeletal integrity and neuropsychiatric disease. Finally, we discuss the current knowledge of endocrine dysregulation in adolescent boys and men with anorexia nervosa, and areas for future research.
Differential diagnosis of anorexia nervosa
Patients with anorexia nervosa usually present with low weight in conjunction with self-induced starvation and intense fear of gaining weight 1 . However, the diagnosis of anorexia nervosa can be difficult because patients with anorexia nervosa can be in denial of their disease and do not view their behaviour and issues with body image as abnormal. In addition, laboratory test results, including complete blood count and chemistry panel, can be entirely normal 14 . Other psychiatric disorders and medical illnesses that can present with weight loss should be considered when appropriate, including depression, malignancy, chronic infections such as tuberculosis, adrenal insufficiency, uncontrolled type 1 diabetes mellitus, hyperthyroidism and malabsorption syndromes 15 . When the patient presents with a history of one of these diagnoses, and/or one of these diagnoses seems plausible after interview or physical exam, appropriate clinical assessment should be pursued. This assessment should include a comprehensive medical history, thorough physical exam and basic screening tests including complete blood count and differential, comprehensive metabolic panel, thyroid function tests, markers of inflammation, urinalysis, faecal occult blood testing and radiologic imaging when appropriate 15 . When anorexia nervosa is in the differential diagnosis, a mental health provider with expertise in eating disorders should then be consulted.
Hypothalamic-pituitary dysfunction
Hypothalamic-pituitary-gonadal axis. The low energy availability in patients with anorexia nervosa commonly results in hypothalamic amenorrhea. In studies from the 1970s, a wide range of luteinizing hormone pulsatility patterns were found in young women with anorexia nervosa who were amenorrheic 16, 17 . These findings ranged from frank apulsatility to patterns characteristic of early puberty, in which luteinizing hormone pulses occurred only during sleep 16, 17 ; return of mature luteinizing hormone pulsatility did not seem to have a simple relationship with weight gain 17 . Investigation into the mechanisms of reduced gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, and consequently reduced gonadotropin secretion from the pituitary, have focused on the role of leptin. Leptin is required for normal reproductive function in starved rodents 18 , and mean serum leptin levels are low in amenorrheic women with anorexia nervosa in association with low fat mass 19 (FIG. 1) . Although administration of exogenous leptin has not been studied in women with anorexia nervosa, exogenous leptin administration restored ovulatory cycles in three of eight women of normal weight who had hypothalamic amenorrhea 20 . However, recombinant human leptin also led to a 4.3% decrease in fat mass among the five individuals who completed the 3-month intervention, which limits the potential of leptin to be used as a therapy in women with anorexia nervosa. In addition, a substantial overlap exists in serum levels of leptin between women with anorexia nervosa who are amenorrheic and those who are eumenorrheic of comparable low weight and psychopathology, such that an individual's serum leptin levels cannot be used for diagnostic purposes 2 . Leptin is a proposed regulator of kisspeptin neurons in the arcuate nucleus of the hypothalamus; kisspeptin signalling is thought to be a key component of the pulse generator that drives pulsatile GnRH secretion 21 . Since its discovery in 1996, mutations in kisspeptin and the kisspeptin receptor have been found to result in a subset of idiopathic hypogonadotropic hypogonadism 22 , and acute administration of exogeneous kisspeptin can lead to gonadotropin release in women with functional hypothalamic amenorrhea 23 . However, no investigators have specifically examined the role of kisspeptin in women with anorexia nervosa, including whether underlying genetic variability in kisspeptin signalling might contribute to individual predisposition to hypothalamic amenorrhea 24 .
Hypothalamic amenorrhea results in low androgen levels, in addition to low oestrogen levels, in women with anorexia nervosa 25 (FIG. 1) . Although recovery of reproductive function occurs in a large percentage of women with anorexia nervosa who are able to achieve an increase in weight and fat mass, no set body weight or percentage of fat mass exists above which menses resume 16 . For example, in one study of 100 adolescent girls with anorexia nervosa, 86% of patients who were able to achieve 90% of ideal body weight had resumption of menses within 6 months 26 . However, amenorrhea persists in up to 15% of women despite recovery of normal body weight 27 . Whether this amenorrhea is because of
Key points
• Anorexia nervosa is associated with endocrine dysregulation, including dysfunction of the hypothalamic-pituitary axis and alterations in adipokines and appetite-regulating hormone levels • Most endocrine abnormalities are adaptive to the state of chronic starvation, but nevertheless might contribute to impaired skeletal integrity, as well as neuropsychiatric symptoms • Weight restoration and gonadal recovery are critical to improving skeletal health, but low bone density and increased fracture risk might remain a long-term complication for individuals in recovery from anorexia nervosa • Further research on the reported associations between hypothalamic-pituitary axis and appetite-regulating hormones with neuropsychiatric symptoms and brain food motivation circuitry might help inform the pathophysiology of the disease Growth hormone-insulin-like growth factor 1 axis. Anorexia nervosa in both adolescents and adults is a state of acquired growth hormone (GH) resistance secondary to chronic nutritional deprivation and is characterized by increased GH secretion but decreased systemic insulin-like growth factor 1 (IGF1) 28, 29 (FIG. 1) .
Increased plasma GH levels with prolonged fasting was first reported in 1963, when the insulin tolerance test as a diagnostic test for GH deficiency was first proposed 30 . In 1999, investigators demonstrated a fourfold increase in daily pulsatile GH secretion and a 20-fold increase in basal GH secretion in women with anorexia nervosa 29 .
In subsequent studies, total and bioactive IGF1 levels were in fact found to be reduced in women with anorexia nervosa despite elevated levels of GH 31, 32 , which is consistent with a state of relative GH resistance at the level of the liver. Low levels of IGF1 might be an adaptive response to preserve energy by decreasing expenditures on growth in states of chronic starvation 33 . GH resistance negatively affects longitudinal bone growth in adolescent boys with anorexia nervosa 34 , but data are conflicting in adolescent girls with anorexia nervosa 35, 36 . Elevated GH levels might also have a protective role by maintaining euglycaemia via gluconeogenesis 37 and mobilizing fat stores via lipolysis 38 in states of chronic starvation. Multiple mechanisms have been proposed to contribute to GH resistance at the level of the liver and the resultant low circulating levels of IGF1, including elevated levels of fibroblast growth factor 21 (FGF21). FGF21, whose production by hepatocytes 39 and white adipocytes 40 is induced by fasting 41 , is thought to inhibit signal transducer and activator of transcription 5 (REF. 42 ), a mediator of intracellular GH effects. Consequently, plasma FGF21 levels are negatively associated with plasma levels of IGF1 (REFS 42, 43) . Low levels of insulin, which are characteristic of states of undernutrition, might also have a role in GH resistance by downregulating hepatic GH receptor expression, as seen in human cell lines 44 . Elevated GH levels are thought to result from the hypothalamic and pituitary gland responses to low circulating IGF1 levels, via classic negative feedback mechanisms 45 ; a smaller contributor might be stimulation of GH secretion by increased ghrelin levels, which is a known GH secreatagogue 46, 47 . GH resistance in individuals with anorexia nervosa is at least partially reversed during refeeding and with weight recovery 31 . IGF1 levels acutely increase with refeeding 48 , and weight gain leads to a normalization of GH secretion 49 . However, during the active disease state, administration of supraphysiologic doses of recombinant GH does not seem to increase levels of IGF1, and might even be detrimental to the patient by leading to a decrease in fat mass secondary to GH stimulation of lipolysis in a patient who is already cachetic 50 .
Hypothalamic-pituitary-adrenal axis. In at least onethird of women with anorexia nervosa, the hypothalamicpituitary-adrenal (HPA) axis is in a chronically stimulated state [51] [52] [53] [54] [55] [56] (FIG. 1) . In classic studies conducted in the late 1970s and early 1980s, 24-hour mean plasma cortisol concentration was elevated in up to 80% of women with anorexia nervosa 51, 52 . In subsequent studies, smaller percentages of women also had elevations in 24-hour urinefree cortisol levels, late night salivary cortisol levels and morning serum cortisol levels on a 1 mg overnight dexamethasone suppression test [53] [54] [55] [56] . Although the degree of hypercortisolaemia correlates inversely with BMI and fat mass 53 , cortisol measures rarely exceed twice the assay upper limit of normal. This hypercortisolaemia might be due to the stress of chronic nutritional deprivation Anorexia nervosa commonly results in hypothalamic amenorrhea, with reduced gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) pulsatility and resultant low estradiol and testosterone levels. Anorexia nervosa is a state of acquired growth hormone (GH) resistance, characterized by increased GH secretion and decreased systemic insulin-like growth factor 1 (IGF1) levels. The hypothalamicpituitary-adrenal axis might be in a chronically stimulated state, with elevated levels of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol. Nonthyroidal illness syndrome, characterized by low levels of T 3 , might be present. Antidiuretic hormone (ADH) might be inappropriately secreted, resulting in free water retention by the kidneys and hyponatraemia. Levels of the adipokine, leptin, are low in anorexia nervosa due to reduced fat mass, whereas adiponectin levels have been variably reported to be unchanged, increased or reduced. Ghrelin, which is orexigenic and appropriately elevated in anorexia nervosa, and PYY, which is anorexigenic and paradoxically elevated in anorexia nervosa, are not depicted in this figure. Ghrelin, in addition to stimulating appetite, also stimulates CRH and GH secretion. *Factors whose levels are variably reported to be unchanged, elevated or reduced. DHEAS, dehydroepiandrosterone sulfate.
and also as a means of maintaining euglycaemia in patients with anorexia nervosa 57 . In addition, increased ghrelin levels in anorexia nervosa might stimulate corticotropin-releasing hormone (CRH) 58, 59 ; decreased metabolic clearance of cortisol might also contribute to hypercortisolaemia 51 . Although anorexia nervosa and Cushing syndrome are two disparate diseases with distinct and very different phenotypes, similarities between the two diseases in the clinical manifestations of hypercortisolaemia are apparent on closer examination. Similar to Cushing syndrome, hypercortisolaemia in women with anorexia nervosa is inversely associated with BMD 55, 56 and positively associated with the severity of depression and anxiety symptoms 56 . Hypercortisolaemia might also inhibit the hypothalamic-pituitary-gonadal axis, and excess cortisol exerts a deleterious effect on muscle; both Cushing syndrome and hypercortisolaemia in women with anorexia nervosa are associated with reduced extremity lean mass 60 . Although reduced caloric intake prevents accumulation of adipose tissue in very low-weight women with anorexia nervosa, during weight recovery, high baseline cortisol levels are associated with trunk fat accumulation, as in patients with Cushing syndrome 61 . Dysregulation of the HPA axis might persist in women with anorexia nervosa after weight gain, which suggests that recovery from anorexia nervosa is not complete despite weight gain or that the HPA axis might be involved in disease pathogenesis [61] [62] [63] . CRH is anorexigenic, and it is hypothesized that increased secretion of CRH in anorexia nervosa might contribute to the severity of weight loss 64 . No pharmacological approaches are currently recommended to address the relative hypercortisolaemia in anorexia nervosa, especially considering that therapies that lower cortisol might result in adrenal insufficiency and/or weight loss.
Whether anorexia nervosa is associated with alterations in the production of adrenal androgen precursors is unclear (FIG. 1) . In one study, levels of dihydroepiandrosterone sulfate (DHEAS) were only lower in women with anorexia nervosa receiving oral contraceptives compared with normal-weight controls, presumably because oral contraceptives reduce levels of albumin, the primary binding globulin for DHEAS 25 . In a further study, basal and adrenocorticotropic hormone 1-24-stimulated dehydroepiandrosterone (DHEA) levels were normal in women with anorexia nervosa 65 . However, other investigators have reported a decrease in DHEAS levels in women with anorexia nervosa compared with a commercial laboratory's normal reference range 66 or a decreased ratio of DHEA to cortisol in women with anorexia nervosa compared with normal-weight controls 67 .
Hypothalamic-pituitary-thyroid axis. Severe weight loss in anorexia nervosa is characterized by the nonthyroidal illness syndrome 68 , a syndrome of abnormalities in thyroid function tests seen in patients with systemic illness, including chronic starvation 69 . In women with very low-weight anorexia nervosa, levels of total T 3 are low, reverse T 3 is elevated due to increased peripheral deiodination of T 4 to reverse T 3 , levels of free T 4 vary from normal to low-normal, and TSH varies from normal to low-normal 47, 55, 68 (FIG. 1) . These abnormalities are an adaptive response to decreased metabolic rate and energy expenditure and, therefore, nonthyroidal illness syndrome does not require treatment. In fact treatment might be harmful to the patient, as thyroid hormone use can itself lead to weight loss and has the potential for abuse 70 . During weight recovery, total T 3 levels normalize 71 .
Posterior pituitary hormones and renal function.
Arginine vasopressin, also known as antidiuretic hormone (ADH), is synthesized by the hypothalamus and stored in the posterior pituitary. ADH is an adrenocorticotropic hormone secretagogue that is upregulated in response to chronic stress in rat models 72 . In humans, depression is associated with elevated levels of ADH in cerebrospinal fluid and enhanced pituitary sensitivity to ADH 73 . Although some investigators have reported that anorexia nervosa is also associated with elevated ADH levels in cerebrospinal fluid, reduced pituitary sensitivity to ADH was also seen, which suggests a greater contribution of anorexigenic CRH than ADH to hyperactivity in the HPA axis seen in anorexia nervosa 64 . Whether this difference between depression and anorexia nervosa is part of the disease pathogenesis or is adaptive is unclear.
Abnormalities in electrolyte concentrations might occur in patients with anorexia nervosa. In one study, 7% of women with anorexia nervosa had hyponatraemia 14 , which is frequently due to inappropriate secretion of vasopressin (that is, the syndrome of inappropriate anti-diuresis (SIAD)) 74 (FIG. 1) . Other causes of low levels of serum sodium in women with anorexia nervosa include excessive water consumption, hypovolaemia due to inadequate nutrition and purging, impaired renal sodium reabsorption in the setting of malnutrition and the use of psychotropic medications that also might lead to SIAD [75] [76] [77] . Although hyponatraemia is generally not severe in women with anorexia nervosa, one cross-sectional study reported serum sodium was as low as 122 mmol/l (normal range 135-145 mmol/l), and one patient reported a history of seizures secondary to hyponatraemia 14 . As severe, and especially acute, hyponatraemia can result in seizures in the absence of any warning 78 , measuring levels of serum sodium is important in these patients. In addition, hypernatraemia has been reported to occur in women with anorexia nervosa due to dehydration or diabetes insipidus, but these cases have been rare 79 . Taking a patient's medical history, physical examination and laboratory test results might help distinguish the cause of hyponatraemia in patients with anorexia nervosa. Water loading as a cause of hyponatraemia is usually clear from a history of excessive water drinking and observation of the same, but if in doubt, a 24-hour urine volume can be helpful to ascertain that the patient has consumed large amounts of water. Assessment of urine sodium levels can be helpful to differentiate hypovolaemia (urine sodium usually <10 mmol/l) from SIAD (urine sodium usually >25 mmol/l) except in women who use diuretics 78 . Hyponatraemia should prompt a consideration of adrenal insufficiency in patients with weight loss but in whom psychiatric symptoms are not prominent 78 .
Other electrolyte abnormalities that might occur in anorexia nervosa include hypokalaemia, hypomagnesaemia and hypophosphataemia. Hypokalaemia is present in ~20% of women with anorexia nervosa, and is nearly exclusively limited to those women who purge (that is, by vomiting, laxative use or diuretic consumption) 14 . Severe hypokalaemia, defined as a serum potassium concentration <2.5 mmol/l, of any cause, is associated with a risk of cardiac arrhythmia 80 . In rare cases, hyperkalaemia might occur in women with anorexia nervosa, such as in those who abuse the diuretic spironolactone. Refeeding syndrome, which might occur as a result of fluid and electrolyte shifts during nutritional rehabilitation, is associated with hypokalaemia, hypophosphataemia, and hypomagnaesemia 81 . During nutritional rehabilitation, carbohydrate intake induces insulin release, which leads to cellular uptake of potassium, magnesium and phosphate 82 . Consequently, electrolyte levels must be closely monitored during the refeeding process, and rapid increases in daily caloric intake should be avoided to try and prevent refeeding syndrome. If refeeding syndrome does occur, nutritional support should be decreased and electrolyte abnormalities aggressively corrected 83 . Anorexia nervosa is also associated with dysregulation of oxytocin secretion, which is an anorexigenic hypothalamic hormone 84 (FIG. 1) . Although nocturnal levels of serum oxytocin are lower in women with anorexia nervosa than in normal-weight individuals 84 , postprandial serum oxytocin levels are higher in women with active and weight-recovered anorexia nervosa than in normal-weight women 85 . One potential explanation for this apparent contradiction is an inverse association between central and peripheral oxytocin levels 86 , such that increased postprandial levels of serum oxytocin indicate an adaptive response to decreased postprandial central oxytocinergic satiety signalling 85 .
Adipokines and appetite-regulating hormones In 1994, leptin was identified as a satiety factor whose deficiency resulted in profound obesity in ob/ob mice 87 .
Since that time, our understanding of leptin as an anorexi genic adipokine has increased substantially. In anorexia nervosa, basal and pulsatile secretion of leptin is reduced in association with reductions in fat mass 88 . In one study, mean overnight levels of serum leptin were 71% lower in adolescent girls with anorexia nervosa than in healthy adolescents 88 . Leptin stimulates secretion of GnRH and hypoleptinaemia might contribute to hypothalamic amenorrhea in anorexia nervosa 18 . In one preclinical study the investigators raise the possibility that hypoleptinaemia might also contribute to elevated levels of physical activity in women with anorexia nervosa for whom compulsive exercise is a component of the psychiatric syndrome 89 . In this study, semi-starvation-induced hyperactivity in rats was prevented and suppressed by leptin administration 89 . In women with anorexia nervosa, endogeneous levels of serum leptin increase with refeeding and weight recovery 90 . However, in one study, 17 out of 18 adolescent girls with anorexia nervosa who achieved their target weight actually had higher serum leptin levels than predicted for their BMI based on a control group of 18 normal-weight age-matched adolescent girls 91 . Whether this relative hyperleptinaemia of weight recovery contributes to resistance to weight gain or recurrent weight loss is unknown.
Adiponectin levels have been variably reported to be unchanged 92 , higher 93, 94 or lower 95 in women with anorexia nervosa than in normal-weight controls (FIG. 1) . In one study, adiponectin levels were higher in women with anorexia nervosa after controlling for fat mass 92, 93 . These differences might relate to assays detecting different circulating adiponectin isoforms 96 . Further research is needed in this area.
Although one would expect increased levels of anorexigenic hormones and suppressed levels of orexigenic hormones in women with anorexia nervosa, this finding has proven to only partially be the case. Ghrelin is an appetite-stimulating hormone that is also a GH and adrenocorticotropic hormone secretagogue 58 , both of which help to maintain euglycaemia during starvation, and an inhibitor of gonadotropin secretion 97, 98 . In one study, mean overnight serum ghrelin levels were 46% higher in 22 adolescent girls with anorexia nervosa than in 18 healthy adolescent girls, and ghrelin levels were inversely associated with BMI 47 . Elevated ghrelin levels seem to be an adaptive response to chronic nutritional deprivation, and decrease with weight gain 99 . However, ghrelin levels might remain higher in women with weight-recovered anorexia nervosa than normal-weight controls 47 . This effect might occur because weight and/or body composition parameters are not normalized for a particular patient and/or because appetite regulation abnormalities might be involved in the pathogenesis of the disease. Whether resistance to ghrelin contributes to the development of anorexia nervosa, or if the elevation in ghrelin levels is simply an appropriate response to chronic starvation, is unknown. In a pilot study of five women with anorexia nervosa, preprandial ghrelin administration was associated with an increase in appetite, suggesting that women with anorexia nervosa are capable of responding to the orexigenic effects of supraphysiologic ghrelin 100 . However, this study was small and not placebo-controlled; further investigation of the potential role of ghrelin in anorexia nervosa is needed. Amplified reduction in ghrelin levels has also been seen during a euglycaemic hyperinsulinaemic clamp in 19 women with anorexia nervosa compared with 26 normal-weight women 101 . This finding raises the question of whether the suppression of ghrelin in response to food intake is exaggerated in anorexia nervosa and might lead to an increased sensation of satiety in such patients.
Peptide YY (PYY), which is secreted by intestinal L cells, is an anorexigenic hormone and serum levels of this hormone are inversely correlated with BMI in adolescent girls with anorexia nervosa 102, 103 (FIG. 1) . Unlike ghrelin, increased serum levels of PYY in adolescent girls and women with anorexia nervosa compared with normal-weight controls is not considered an adaptive response because one would expect PYY levels to be low in anorexia nervosa as PYY suppresses appetite. Elevated levels of PYY in anorexia nervosa might contribute to decreased nutrient intake and disordered eating psychopathology 104 , and might also remain elevated despite weight gain 105 .
Skeletal integrity BMD and bone microarchitecture. Global endocrine dysregulation in anorexia nervosa has deleterious consequences on skeletal health and reduced BMD is a common comorbidity. In one study of 214 women with anorexia nervosa and a mean age of 25 years, 52% of women had osteopenia (BMD T-score less than −1.0 at one or more sites) and 34% had osteoporosis (BMD T-score below −2.5 at one or more sites) -only 13.8% had normal BMD at all skeletal sites 14 . Similarly, in a study of 60 adolescent girls with anorexia nervosa and a mean age of 15.8 years, 52% had BMD Z-scores less than −1.0 at one or more sites 106 . In addition, alterations in both cortical and trabecular bone microarchitecture and bone strength have been identified in adolescent girls and young women with anorexia nervosa using high resolution peripheral quantitative CT [107] [108] [109] . Despite the young age of individuals with anorexia nervosa, this decrement in BMD does indeed translate into an increase in fracture risk. For example, the nonspinal fracture rate was found to be seven times higher in women with anorexia nervosa compared with normal-weight agematched women 110 , and in a meta-analysis, the disease was found to be associated with an increased likelihood of both osteoporosis (OR 12.59, 95% CI, 3.30-47.9, P <0.001, I 2 = 0%, from four studies) and fractures (OR 1.84, 95% CI 1.17-2.89, P = 0.008, I 2 = 56, from six studies) in women 111 . The prevalence of fractures is also 59.8% higher in adolescent girls with anorexia nervosa than in healthy controls (31.0% versus 19.4%, P = 0.02), and fracture prevalence remains elevated in adolescent girls with anorexia nervosa even when BMD is normal or only modestly reduced 112 . This finding might be the result of alterations in bone microarchitecture -that is the 3D organization and distribution of bone, which is an important determinant of bone strength that cannot be measured by dual-energy X-ray absorptiometry 113 . Adolescence is normally a period of high bone turnover, with bone formation exceeding bone resorption as peak bone mass accrues 114 . In contrast to healthy adolescents, in whom continued bone accrual occurs to attain peak bone mass, adolescents with anorexia nervosa have decreased bone formation and bone resorption compared with Tanner stage-matched normal-weight controls 115 . Accrual of bone, therefore, plateaus early 115 and optimum peak bone mass is not achieved, which impairs future bone health and increases fracture risk. By contrast, bone loss in women with anorexia nervosa reflects a decrease in bone formation and an increase in bone resorption. For both adolescents and adults, decreased BMD can occur relatively rapidly in anorexia nervosa, with changes often apparent after just 1 year of disease 116 . Moreover, the duration of illness is associated with a lower BMD 117 , suggesting that bone loss might continue throughout the course of the illness.
Determinants of impaired BMD.
Factors that contribute to low BMD in anorexia nervosa include low weight and abnormalities in body composition, anterior and posterior pituitary hormone dysregulation, and abnormalities in adipokine and gut peptide secretion. Reduced BMI is associated with low BMD in adolescent girls and women with anorexia nervosa 106, 118 ; the resultant aberrations in body composition as weight loss occurs might further contribute to bone loss. For example, muscle has an anabolic effect on bone through mechanical loading and hormonal crosstalk, and low lean body mass is associated with impaired BMD and bone microarchitecture in both adolescent girls and women with anorexia nervosa 106, 119 . Fat depots also have important roles in regulating bone mass in anorexia nervosa. A relatively new area of investigation is bone marrow adipose tissue mass, which is paradoxically elevated in women with anorexia nervosa despite reduced total body fat 120, 121 . One of the mechanisms underlying the increase in bone marrow adipose tissue in anorexia nervosa might be preadipocyte factor 1 (PREF1), which is an important regulator of mesenchymal stem cell differentiation into either the osteoblast or adipocyte lineage 122 (FIG. 2) . In one study, 20 women with anorexia nervosa had significantly higher mean levels of PREF1 than normal-weight controls (0.46 ± 0.03 versus 0.37 ± 0.02 ng/ml, P = 0.01), and PREF1 was associated with increased bone marrow adipose tissue mass in women with anorexia nervosa 122 . However, PREF1 is only one of many factors that contribute to the interplay between osteoblast and adipocyte differentiation. Bone marrow adipose tissue mass is inversely associated with BMD in patients with anorexia nervosa 121 ; whether bone marrow adipose tissue has a causal role in low BMD or simply expands to fill the space in the absence of haematopoetic and boneproducing cells is unclear. Further research is needed to determine the mechanisms underpinning, and the implications of, this fat depot, which is dynamic and has been demonstrated to decrease with weight recovery 123 . Anterior pituitary hormones are important determinants of BMD; GH resistance that results in relative IGF1 deficiency is a major contributor to bone loss in women with anorexia nervosa 28, 108 . GH and IGF1 both stimulate osteoblast differentiation while inhibiting osteoclast differentiation, and GH independently stimulates osteoblast proliferation 124 (FIG. 2) . Accordingly, low serum levels of IGF1 in women with anorexia nervosa are associated with low levels of markers of bone formation such as serum osteocalcin 48, 115 , low BMD 115 and impaired bone microarchitecture 108 . By contrast, cortisol decreases bone formation and increases bone resorption, in part by inhibiting osteoprotegerin secretion, a factor that inhibits osteoclastogenesis and osteoclast activity, and increases receptor activator of nuclear factor κ B ligand (RANKL) secretion, which increases osteoclastogenesis and osteoclastic activity 125 (FIG. 2) . Consequently, measures of cortisol levels are inversely associated with BMD in adolescent girls and women with anorexia nervosa 55, 56 . Oestrogen primarily inhibits bone resorption, in part by inhibiting the secretion of inflammatory cytokines and RANKL and increasing the secretion of osteoprotegerin 126 . Oestrogen might also stimulate bone formation by inhibiting sclerostin secretion, a factor that inhibits osteoblast (FIG. 2) . Testosterone levels, which are also reduced in amenorrheic women with anorexia nervosa, exert primarily anabolic effects on bone 128 (FIG. 2) .
Consequently, the duration of amenorrhea, as a proxy for gonadal steroid deficiency, is negatively associated with BMD in women with anorexia nervosa 129 . ADH and oxytocin, hypothalamic hormones that are stored in the posterior pituitary, are also important for normal bone metabolism 84, 130 . Hyponatraemia is associated with reduced BMD in a rodent model of SIAD 131 , and oxytocin deficiency is also associated with low BMD in oxytocin and oxytocin receptor null mice 132 . Similar to preclinical studies, hyponatraemia 130 is associated with decreased BMD in women with anorexia nervosa independent of BMI; low nocturnal serum oxytocin levels 84 are also associated with decreased BMD. In addition, alterations in adipokines and appetiteregulating hormones might contribute to low bone mass in anorexia nervosa. Preclinical data regarding the action of leptin on the bone microenvironment are complex, and suggest a central inhibitory effect via the sympathetic nervous system 133 , but also a peripheral stimulatory effect of leptin on bone metabolism 134 (FIG. 2) . Moreover, the effects of leptin on bone might not be uniform throughout the skeleton, as leptin-deficient ob/ob mice have decreased femoral BMD but increased spine BMD 135 . In women Figure 2 | The effect of endocrine dysregulation on the bone microenvironment. Bone marrow adipose tissue is paradoxically elevated in anorexia nervosa despite reduced total body fat. Elevated levels of preadipocyte factor 1 (PREF1), which are an important regulator of mesenchymal stem cell differentiation, might be one of the mechanisms underlying the increase in bone marrow adipose tissue. Overall, a decrease in osteoblast differentiation, proliferation and activity with a concomitant increase in osteoblast apoptosis is seen, in addition to an increase in osteoclast differentiation, proliferation and activity with a concomitant decrease in osteoclast apoptosis. Growth hormone (GH) and insulin-like growth factor 1 (IGF1) stimulate osteoblast differentiation while inhibiting osteoclast differentiation, and GH independently stimulates osteoblast proliferation. By contrast, cortisol decreases bone formation and increases bone resorption. Alterations in adipokines, such as leptin, and appetite-regulating hormones, such as peptide YY (PYY), might also contribute to impaired bone microarchitecture in anorexia nervosa but are not well understood. *Hormone effect for which there are limited data. +, positive effect; -, negative effect.
with anorexia nervosa, hypoleptinaemia is independently associated with low BMD at both the femoral neck and spine, as well as abnormalities in bone microarchitectural parameters, independently of BMI 108 . Adiponectin, which might or might not be elevated in women with anorexia nervosa (these data are conflicting), can affect osteoblastogenesis either positively 136 or negatively 137 while suppressing osteoclastogenesis 136 . PYY might inhibit osteoblastic activity while increasing osteoclastic activity 138 (FIG. 2) . Consistent with these data, mean overnight PYY levels are strongly inversely associated with BMD in women with anorexia nervosa independently of BMI 103 . The relative contributions of these factors on impaired BMD and bone microarchitecture in anorexia nervosa are not well understood and are a focus of current research.
Management of impaired BMD.
The effects of hormone replacement on BMD in adolescent girls and women with anorexia nervosa are complex. Oral oestrogen is not effective in increasing BMD in adolescent girls and women with anorexia nervosa, as shown in randomized controlled trials [139] [140] [141] (TABLE 1) . One contributing factor might be that oral oestrogen decreases IGF1 production by the liver 142 . By contrast, in adolescent girls, physiological transdermal oestrogen replacement with cyclic progesterone increases spine and hip BMD and prevents the decline in BMD Z-scores observed in untreated girls with anorexia nervosa 143 . However, such therapy is not sufficient to normalize BMD 143 , possibly because it does not correct other hormonal abnormalities that are important for skeletal health as described earlier in the text. In addition, replacement of androgens, in the form of testosterone or DHEA, does not improve BMD as compared with placebo in small randomized controlled trials 144, 145 , although, when combined with an oral contraceptive, one study showed that DHEA might maintain BMD in adolescent girls and young women with anorexia nervosa 146 . Preliminary data suggest that in women with anorexia nervosa, IGF1 replacement might prevent bone loss when administered alone and improve BMD at the spine by a mean of 1.8% in combination with oral contraceptives, but does not normalize BMD 147 . In this study, oral contraceptives alone appeared to maintain, though not increase, BMD 147 . A small study of 20 adolescent girls with anorexia nervosa has also shown an increase in levels of bone formation markers such as procollagen type 1 N-terminal propeptide (P1NP) following recombinant human IGF1 (rhIGF1) administration 148 . The change in levels of P1NP over the study duration was significantly higher (29.4 ± 9.8 versus 2.5 ± 4.8%, P = 0.02) in adolescent girls with anorexia nervosa who received rhIGF1 than those who did not.
Bisphosphonates and teriparatide, which are approved for the treatment of postmenopausal osteoporosis, have also been studied in anorexia nervosa (TABLE 1) . In a trial investigating the use of risedronate in 77 women with anorexia nervosa, 1 year of treatment with risedronate decreased the bone resorption marker C-terminal telopeptide (CTX) by 41% (95% CI 17-65%, P = 0.002), postero-anterior spine BMD increased by 3.2% (95% CI 1.8-4.6%, P <0.0001), and total hip BMD increased by DHEA, Dehydroepiandrosterone; hIGF1, human insulin-like growth factor 1.
1.9% (95% CI 0.4-3.4%, P = 0.013) compared with placebo 144 . However, in a randomized controlled trial of bisphosphonate therapy in 32 adolescent girls with anorexia nervosa (mean age 16.9 ± 1.9 years), no increase in spine BMD was seen compared with placebo 149 . This lack of effect might be because bisphosphonates decrease bone turnover, which is already reduced in adolescents with anorexia nervosa, or because girls in both trial arms gained a substantial amount of weight (13.5 ± 9.9% for the intervention group versus 16.2 ± 16.4% for the control group; P = 0.59), which might have overwhelmed the detectable response to bisphosphonate therapy. Bisphosphonates are not FDA-approved for use in girls or women of childbearing age with anorexia nervosa because these drugs cross the placenta and some have a long half-life, meaning they can be released slowly from bone over a period of years 150 . Consequently, bisphosphonates should be used with caution in girls and in women of child-bearing age and only after a thorough discussion of the risks and benefits, and should be avoided altogether in women who are seeking pregnancy in the near future.
In one study, teriparatide, which is a potent bone anabolic agent, increased spine BMD substantially (6-10%) after only 6 months of therapy in older women (mean age 47 years) with anorexia nervosa 151 , and might, therefore, be a promising therapy. However, further data, including with subsequent antiresportive consolidation therapy, are needed. Notably, teriparatide is associated with an increased incidence of osteosarcoma in rats in a dose and time-dependent manner 152 , and an FDA warning advises that this medication should not be prescribed to patients who are at increased baseline risk of osteosarcoma, including paediatric and young adult patients with open epiphyses 153 .
The most important strategy to improve BMD in anorexia nervosa is treatment of the underlying eating disorder with recovery of weight and menstrual function. For example, in one study of 75 women with anorexia nervosa the mean annual increase in BMD was 1.8% at the hip and 3.1% at the spine for those who gained weight and resumed menses. In those who remained low weight and amenorrheic, the annual rate of decline was −2.4% at the hip and −2.6% at the spine in this study 119 . Despite a comparable amount of weight gained, those women who resumed menses had a mean annual increase in BMD of 3.1% at the spine, while those who did not recover menstrual function demonstrated a mean annual decline in BMD of −2.4% at the spine. This finding suggests that normalization of reproductive function in addition to weight gain is necessary for maximal skeletal recovery. However, despite the combination of weight gain and resumption of menses, BMD does not normalize in all women 154 , especially for those who have not achieved their peak bone mass due to anorexia nervosa. In one small study of 19 women recovered from anorexia nervosa for a mean period of 21 years, mean BMD at the femoral neck was still significantly lower (0.922 versus 1.073 g/cm 2 , P = 0.004) than in healthy controls 155 . Investigators in another study reported that peripheral quantitative CT measurements at the tibia, including total volumetric BMD at 14% tibia length, were significantly lower (528 ± 70 versus 486 ± 84 mg/cm 3 ; P <0.05) in a group of 22 women in recovery from anorexia nervosa for a mean of 27 years compared with healthy controls 156 . Adolescent girls and women with active or recovered anorexia nervosa might assume that calcium and vitamin D supplementation alone is sufficient to normalize BMD, but this is not effective for two reasons. Firstly, calcium and vitamin D supplementation alone cannot overcome the short-term and long-term detrimental effects of anorexia nervosa on bone mass 14 . Secondly, as a group, adolescent girls and women with anorexia nervosa already have comparable or higher intakes of both calcium and vitamin D, predominantly through supplementation, than normal-weight controls 157, 158 . As decreased BMD is often a long-term complication of anorexia nervosa, development of FDA-approved therapies to treat bone loss and reduce fracture risk in women with anorexia nervosa will have important positive public health implications. In the interim, dual-energy X-ray absorptiometry evaluations remain useful to demonstrate the detrimental effects of anorexia nervosa on bone, to counsel patients regarding fracture risk and to motivate patients to pursue eating disorder treatment.
Neuropsychiatric comorbidities
Anxiety and depression are common comorbid conditions in women with anorexia nervosa, present in 50-75% of patients 159 . Anxiety and depression, as well as eating disorder psychopathology, are associated with dysregulation of hormones, including oestrogen, androgen, cortisol, leptin, PYY and oxytocin levels 56, 85, 104, [160] [161] [162] . Oestrogen deficiency might negatively affect mood and anxiety 161, 163 . For example, in rat models, ovariectomy resulting in hypoestrogenaemia is associated with increased anxiety 164 . In addition, fear extinction, or the gradual decrease of a conditioned fear response, was impaired in female rats during the metestrus phase (low oestrogen/progesterone) compared with male rats 165 . Similarly, hypoandrogenaemia has been associated with increased severity of depression and anxiety scores in women with anorexia nervosa independent of weight 160 , which is consistent with data demonstrating increased depression and anxiety scores in men with hypogonadism 166 . Depression and anxiety measures are also positively associated with levels of serum cortisol 56 , and negatively associated with serum leptin levels 162 ; the latter association remained significant after controlling for body fat or weight 162 . Measures of eating disorder psychopathology have been positively associated with serum cortisol and PYY levels independent of BMI 104 , and negatively associated with elevated levels of serum leptin 162 , in women with anorexia nervosa. Postprandial levels of oxytocin are also associated with increased eating disorder psychopathology, anxiety and depression scores in anorexia nervosa 85, 167 . The effect of hormone-replacement therapy on eating disorder psychopathology with comorbid depression and anxiety is less clear. In one study, gonadal steroid sufficiency, either through resumption of menses or oral contraceptive use, rather than weight recovery alone, was an important predictor of improved cognitive function (as assessed by a comprehensive neuropsychological evaluation using the Standard Battery of the Woodcock-Johnson III, the Hopkins Verbal Learning Test-Revised, and the visual reproduction subscale of the Wechsler Memory Scale-Revised) in 66 women with anorexia nervosa compared with 42 normal-weight controls 168 . In adolescent girls aged 13-18 years old with anorexia nervosa, an estradiol patch improved trait anxiety (that is, the tendency to experience anxiety) independently of weight changes, but did not affect attitudes toward eating, eating behaviours or body shape perception 169 . Pilot studies administering low-dose testosterone patches at a dose of 300 mcg/day to women without anorexia nervosa suggest that this treatment might have positive effects on mood [170] [171] [172] . However, whether low-dose testosterone would be beneficial for the treatment of comorbid mood disorders in women with anorexia nervosa is unclear.
Anorexia nervosa in men
Although 5-15% of those affected by anorexia nervosa are men, very limited data exist regarding the endocrine impact of the disease in this population. Adolescent boys with anorexia nervosa are known to have lower BMI, lean mass, fat mass, testosterone levels and levels of estradiol than normal-weight controls 173 . Men with anorexia nervosa have a higher percentage trunk fat and a higher trunk-to-extremity fat ratio than healthy men after controlling for weight 174 . This finding is attributed to hypogonadotropic hypogonadism, as men with acquired hypogonadism have greater waist-to-hip circumferences and abdominal subcutaneous fat than eugonadal men, and testosterone replacement results in a decrease in these measures [175] [176] [177] . In a small longitudinal study of three men with anorexia nervosa, levels of serum testosterone increased into the normal range of a commercial laboratory assay with weight gain 178 . Adolescent boys and men with anorexia nervosa also have reduced BMD 173 . The proportion of adolescent boys aged 12-19 years with anorexia nervosa who have BMD Z-scores below −1.0 at the femoral neck and spine are 65% and 50%, respectively, compared with 18% and 24% for normal-weight adolescent boys 173 . Low BMD Z-scores at the hip and femoral neck are more common in adolescent boys with anorexia nervosa (58.8% and 64.7%, respectively) compared with adolescent girls with anorexia nervosa (20% and 13.6%, respectively), for whom BMD is more affected at the lumbar spine 106, 173 . The sex-specific effects of anorexia nervosa on BMD suggest that not all data from women can be extrapolated to the male population. Data on the efficacy of testosterone replacement on BMD in adolescent boys or men with anorexia nervosa are not available. Fracture data in men with anorexia nervosa is largely unknown and limited to case reports 179, 180 ; studies have been limited by impediments in recruiting large numbers of patients given the lower prevalence of eating disorders in men than women, delays in diagnosis or even failure to recognize the disease in men.
Future research directions Future research should include elucidating the mechanistic and genetic bases for individual predisposition to endocrine dysregulation in adolescents, women and men with anorexia nervosa, as well as to the aetiopathology of the disease itself. Further research is also needed to understand the interplay between appetite-regulating hormones and brain food motivation circuitry, specifically in anorexia nervosa. The pathophysiology of bone loss and psychiatric comorbidities in anorexia nervosa is also incompletely understood, and optimal treatment strategies still need to be developed. Much less is known about anorexia nervosa in adolescent boys and men than girls and women, and should be an active area of investigation. Endocrine dysregulation in other eating disorders, such as normal-weight women with bulimia nervosa, is also an area in need of active investigation. In some studies, investigators report that women with bulimia nervosa have BMD comparable to healthy controls 181 , but others report that those women who have a history of low weight and/or amenorrhea are at risk of bone loss 182 . Another group of women, for whom a history of low weight and/or amenorrhea is associated with deleterious effects on BMD despite current normal weight, includes those with atypical anorexia nervosa 183 . Atypical anorexia nervosa is a new formal diagnosis within OSFED of DSM-5 for individuals who meet anorexia nervosa psychological criteria but are not low weight 183 .
Conclusions
Anorexia nervosa is associated with global endocrine dysregulation, including dysfunction of the hypothalamic-pituitary axis and alterations in adipokines and appetite-regulating hormone levels. Most of these endocrine abnormalities are adaptive but nevertheless might contribute to impaired skeletal integrity as well as neuro psychiatric symptoms. Specifically, hypogonadism, hypercortisolaemia, GH resistance, hypooxytocinaemia and hyponatraemia are all among the endocrinology factors that might contribute to reduced BMD, which is a common and severe long-term complication in patients with anorexia nervosa. Weight restoration and gonadal axis recovery are crucial for the improvement of skeletal health, but low BMD might persist despite recovery of the eating disorder. Currently, no FDA-approved medications exist to treat low BMD in anorexia nervosa. The reported associations between hypothalamic-pituitary axis and appetite-regulating hormones with neuro psychiatric disease in anorexia nervosa might provide promising avenues for treatment. As most of the endocrine abnormalities observed in anorexia nervosa are adaptive to the state of chronic starvation, management consists of treatment of the underlying eating disorder via a team approach, which typically includes a psychologist and/or psychiatrist, primary care physician and nutritionist.
